US-based pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from ...

President of Lilly Diabetes and Obesity and President of Lilly USA; Eli Lilly and Co Anne White; Executive Vice President, President - Lilly Neuroscience; Eli Lilly and Co Good morning.

The risks to success for Alzheimer’s drug Kisunla remain high because of bottlenecks in patient diagnosis, required scans and monitoring ... diabetes, obesity, and overweight patients with Lilly ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast Eli Lilly ...

Diabetes and Obesity Drugs Fuel Eli Lilly Profit in the Final Quarter of 2024 Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company's quarterly earnings ...

(AP) — Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the Indianapolis-based drugmaker came out with a mostly better-than ...

Eli Lilly (NYSE:LLY) on Thursday reported its Q4 ... LLY’s GLP-1 therapy tirzepatide, branded as Mounjaro and Zepbound for diabetes and weight loss, respectively, powered the company’s Q4 ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast. Sales of ...